¿Es tiempo de vacunar a la mujer embarazada contra la coqueluche?
Author
dc.contributor.author
Cofré Guerra, José
Admission date
dc.date.accessioned
2016-06-24T15:55:02Z
Available date
dc.date.available
2016-06-24T15:55:02Z
Publication date
dc.date.issued
2016
Cita de ítem
dc.identifier.citation
Rev Chilena Infectol 2016; 33 (1): 55-58
en_US
Identifier
dc.identifier.issn
0716-1018
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/139124
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
Pertussis may cause death in neonates and very young infants. In these ages pertussis vaccine has not been
administered yet or infants haven’t received enough doses of vaccine to protect them. Cocoon strategy have been
implemented in several countries and has limited efficacy because of low coverage among households. In vaccinated
pregnant women transplacental transfer of pertussis antibodies starts at 32-34 weeks of pregnancy. United
Kingdom, The United States of America and afterward other countries in Europe and America have adopted this
strategy. Recent British research about security and effectiveness of pertussis vaccination in pregnant women to
reduce pertussis incidence and fatality cases in neonate and very young infants infant support this strategy despite
the fact that controlled studies about the efficacy and security in mothers and neonates have not been published.
Several studies still not published or in progress are trying to answer these two questions and to evaluate possible
interference between transplacentaly transferred pertussis antibodies and infants immune response to routine
vaccines. Recently WHO has recommended pertussis vaccination during pregnancy in countries where neonatal
pertussis is a public health problem. Nowadays, Chilean experts discuss if pertussis vaccination of pregnant women
must be adopted in our country.